Company: DNLI
Filing Date: 2025-06-03
Form Type: 8-K
Source: 0001714899-25-000128
Chunk: 1

Company: Denali Therapeutics Inc.
Filing Date: 2025-06-03
Form: 8-K
Item: Item 5.07
Chunk 1
---
Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 3, 2025, the Company held its annual meeting of stockholders. Of the 145,242,212 shares of common stock outstanding as of April 9, 2025, the record date for the meeting, 131,067,862 shares of common stock were represented at the meeting in person or by proxy, constituting 90.2% of the outstanding common stock entitled to vote. The matters voted upon at the meeting and the vote with respect to each such matter are set forth below:

Proposal 1 - Election of Directors

Election of three Class II directors to hold office until the 2028 annual meeting of stockholders. Each of the following nominees was elected to serve as a Class II director, to hold office until the Company’s 2028 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.

  Nominees                   For        Withheld      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────────────
  Julian Baker        98,032,346      22,859,131            10,176,385  
  Peter Klein        106,248,604      14,642,873            10,176,385  
  Steve Krognes       64,815,389      56,076,088            10,176,385  

Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm

The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified based on the following results of voting:

          For      Against      Abstain      Broker Non-Votes  
 ───────────────────────────────────────────────────────────────
  130,831,208      194,182       42,472      —                 

Proposal 3 - Advisory Vote to Approve Executive Compensation

The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.

          For         Against      Abstain      Broker Non-Votes  
 ──────────────────────────────────────────────────────────────────
  109,412,774      10,796,945      681,758            10,176,385  

Item 9.01 Financial